EvergreenHealth is seeking participants for a clinical trial focused on Postural Orthostatic Tachycardia Syndrome (POTS), a disorder linked to Long COVID. This initiative is in partnership with the National Institute of Health’s RECOVER Initiative, which is dedicated to understanding and treating the long-term effects of COVID-19. The trial is open to adults who have tested positive for COVID-19 and continue to experience symptoms such as fast heart rate, dizziness, and persistent fatigue. Principal Investigator Dr. Diego Lopez de Castilla highlighted the significance of this research in advancing the understanding of Long COVID and enhancing treatment options for affected individuals.

The study will evaluate two specific interventions: Gamunex-C, a form of intravenous immunoglobulin that aids in immune response, and Ivabradine, which is intended to help manage heart rate. This research is critical as it addresses the ongoing health challenges faced by many post-COVID patients, contributing to a broader understanding of autonomic dysfunction. Those interested in participating can learn more by visiting EvergreenHealth's website. The outcomes of this study could pave the way for improved care and management strategies for patients grappling with the aftermath of COVID-19.